


**AMENDMENTS****In the specification**

Please amend the specification by deleting the term "said" from line 2 of the Abstract. A new abstract is attached to this response.

**In the claims**

Please amend the claims as follows, without prejudice or disclaimer:

5. An isolated nucleic acid molecule encoding an immunogenic peptide derived from prostate-specific antigen, the peptide being capable of eliciting an immune response for treating prostate cancer and consisting of an amino acid sequence as defined by Formula I:



wherein

n=0 or 1 ;

each X<sub>1</sub> is independently selected from leucine or methionine;

each X<sub>2</sub> is independently selected from valine or leucine; and

each X is independently selected from any amino acid,

and fragments, elongations, analogs or derivatives of the PSA derived peptides.

6. (Amended) An isolated nucleic acid encoding a PSA derived peptide according to claim 5 comprising:

- a) the nucleic acid sequence as shown in any one of SEQ ID NOS.:7-9 wherein T may also be U;
- b) a nucleic acid sequence that is complementary to a nucleic acid sequence of (a);
- c) a nucleic acid sequence that has at least 90% homology to a nucleic acid sequence of (a) or (b);
- d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b), or (c); or
- e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c), or (d) under stringent hybridization conditions.

*(B3)* 9. (Amended) An isolated host cell transformed with an expression vector of claim  
8.

*(B4)* 20. (Amended) A method of treating prostate cancer comprising administering to an animal an effective amount of a peptide in accordance with claim 5.